Published in Mov Disord on April 15, 2010
Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology (2013) 1.53
Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's disease. Mov Disord (2013) 1.45
Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol (2011) 1.26
Mild cognitive impairment in Parkinson's disease. Minerva Med (2011) 1.19
Premotor and nonmotor features of Parkinson's disease. Curr Opin Neurol (2014) 1.12
Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease. PLoS One (2011) 0.92
Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy. Hum Brain Mapp (2014) 0.89
Early cortical gray matter loss and cognitive correlates in non-demented Parkinson's patients. Parkinsonism Relat Disord (2013) 0.84
Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process. Brain (2014) 0.84
Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain (2015) 0.83
Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease. Mov Disord (2015) 0.81
Grey matter changes in cognitively impaired Parkinson's disease patients. PLoS One (2014) 0.79
Mapping cortical atrophy in Parkinson's disease patients with dementia. J Parkinsons Dis (2013) 0.79
Mild cognitive impairment in Parkinson's disease: a review of current concepts. Neurol Res Int (2013) 0.78
Dementia and neuroimaging. J Neurol (2012) 0.77
Reduced CA2-CA3 Hippocampal Subfield Volume Is Related to Depression and Normalized by l-DOPA in Newly Diagnosed Parkinson's Disease. Front Neurol (2017) 0.75
Cortical Thickness, Surface Area and Subcortical Volume Differentially Contribute to Cognitive Heterogeneity in Parkinson's Disease. PLoS One (2016) 0.75
Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. Neurodegener Dis Manag (2015) 0.75
Magnetic resonance imaging for the diagnosis of Parkinson's disease. J Neural Transm (Vienna) (2017) 0.75
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Alzheimer's disease. Lancet (2011) 5.35
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol (2003) 4.76
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ (2011) 4.37
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol (2005) 3.31
[Not Available]. Tidsskr Nor Laegeforen (2016) 3.12
Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord (2006) 2.96
A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord (2008) 2.81
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord (2006) 2.47
Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology (2007) 2.32
Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. Mov Disord (2014) 2.30
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry (2004) 2.21
Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol (2013) 2.19
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol (2009) 2.10
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord (2006) 2.04
Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord (2012) 1.99
Association of hippocampal atrophy with cerebrospinal fluid antibodies against the NR2 subtype of the N-methyl-D-aspartate receptor in patients with systemic lupus erythematosus and patients with primary Sjögren's syndrome. Arthritis Rheumatol (2014) 1.97
Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet (2012) 1.88
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol (2012) 1.86
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol (2013) 1.83
Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci (2005) 1.76
Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol (2006) 1.76
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol (2010) 1.70
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry (2013) 1.69
Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord (2005) 1.68
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 1.66
Optical coherence tomography in multiple sclerosis. Lancet Neurol (2006) 1.65
Cigarette smoking in Parkinson's disease: influence on disease progression. Mov Disord (2004) 1.61
Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2010) 1.59
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord (2007) 1.55
CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry (2010) 1.55
Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord (2009) 1.54
Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry (2009) 1.54
Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology (2005) 1.53
Epidemiology of psychosis in Parkinson's disease. J Neurol Sci (2009) 1.51
Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study. J Neuroimaging (2003) 1.51
Neuropsychological profile of patients with Parkinson's disease without dementia. Dement Geriatr Cogn Disord (2003) 1.51
Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol (2011) 1.51
CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2010) 1.50
The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology (2013) 1.48
Validation of the Unified Parkinson's Disease Rating Scale (UPDRS) section I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease. Parkinsonism Relat Disord (2007) 1.48
Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--the Bergen District Nursing Home Study (BEDNURS). Int J Geriatr Psychiatry (2008) 1.47
Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. J Neuroimmunol (2012) 1.46
Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.44
A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry (2006) 1.39
Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci (2007) 1.39
Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol (2004) 1.33
Predictors and course of health-related quality of life in Parkinson's disease. Mov Disord (2008) 1.33
Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proc Natl Acad Sci U S A (2009) 1.32
Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. Mov Disord (2010) 1.31
Altered NK cell development and enhanced NK cell-mediated resistance to mouse cytomegalovirus in NKG2D-deficient mice. Immunity (2009) 1.29
Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol (2011) 1.29
Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry (2010) 1.28
Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. J Neurol Sci (2009) 1.28
Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage (2011) 1.27
The effect of staff training on agitation and use of restraint in nursing home residents with dementia: a single-blind, randomized controlled trial. J Clin Psychiatry (2010) 1.25
Assessment and treatment of pain in people with dementia. Nat Rev Neurol (2012) 1.22
Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited. Neuropsychology (2011) 1.22
Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method. Neuroimage (2004) 1.22
Optimised anaesthesia to reduce post operative cognitive decline (POCD) in older patients undergoing elective surgery, a randomised controlled trial. PLoS One (2012) 1.21
Who suffers most? Dementia and pain in nursing home patients: a cross-sectional study. J Am Med Dir Assoc (2008) 1.20
Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol (2005) 1.19
HIV-associated alterations in normal-appearing white matter: a voxel-wise diffusion tensor imaging study. J Acquir Immune Defic Syndr (2007) 1.18
Use of MR venography for characterization of the extracranial venous system in patients with multiple sclerosis and healthy control subjects. Radiology (2010) 1.18
Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. J Neurol Neurosurg Psychiatry (2007) 1.17
Depression in dementia: epidemiology, mechanisms, and treatment. Curr Opin Psychiatry (2011) 1.17
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol (2013) 1.16
The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson's disease. Int J Geriatr Psychiatry (2002) 1.15
Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation (2011) 1.11
Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation (2010) 1.11
Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. J Neurol Sci (2009) 1.11
Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry (2005) 1.11
Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clin Neuropsychol (2010) 1.10
Frequency and correlates of caregiver-reported sleep disturbances in a sample of persons with early dementia. J Am Geriatr Soc (2010) 1.09
Recent developments in imaging of multiple sclerosis. Neurologist (2011) 1.09
Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord (2010) 1.09